Mr Phil Willis MP, Chairman of the House of Commons’ Science and Technology Select Committee, who unveiled the plaque said, “It is a huge privilege to officially open the new ‘Minerva’ research facility which offers emerging biotech companies state of the art facilities to bring excellent science to the market. This facility is a superb example of how government funding can stimulate knowledge transfer by sponsoring direct links between academia and industry and stimulating wealth creation in the regions.”
Minerva is the first of three BioDevelopment buildings, offering flexible laboratory and office accommodation, which are anticipated will stimulate and facilitate the knowledge transfer process from research to commercial exploitation on the campus. Dr David Hardman, CEO of BBT said, “This BioDevelopment building is the latest development in our Babraham Research Campus strategy to integrate world class science with innovative bioventures to exploit new technologies relating to human healthcare. This building enables companies to expand into new facilities on flexible terms, a unique proposition in the region. The campus has been home to over 40 of the region’s biotechnology companies since it opened in 1998 and BBT will start a new Bioincubator building in September. The continued success emphasises the role our knowledge-based campus can play in promoting biosciences for regional development.”
Cambridge Biotechnology Ltd, a drug-discovery research company developing novel therapeutics for the treatment of pain, inflammation and obesity, is one of the four companies residing in Minerva. Dr Peter Richardson, Managing Director of CBT said, "Moving to new facilities at Babraham represents a major new phase in the growth of CBT. The new laboratories will provide CBT's drug discovery teams with excellent working conditions and will ensure optimal efficiency and safety for all its research staff. A location on the Babraham Research Campus also benefits from the proximity of a host of innovative biotech companies and prestigious academic groups which provides an optimal environment for a company such as CBT to thrive."
Also in Minerva are NovaThera Ltd, a spin-out from Imperial College London that is pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering, and Stem Cell Sciences plc, an international company with centres in the United Kingdom, Australia, Japan and the USA. Active in the stem cell research field since 1994, the company is principally focused on expertise to grow, differentiate, select and purify stem cells. Cyclacel, the Dundee-based biopharmaceutical company dedicated to the discovery, development and commercialisation of novel, mechanism-targeted drugs to treat human cancers, moved into Minerva from the Bioincubator facilities earlier this year.
Claire Cockcroft | alfa
Historical rainfall levels are significant in carbon emissions from soil
30.05.2017 | University of Texas at Austin
3D printer inks from the woods
30.05.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt
Scientists have developed a new method of characterizing graphene’s properties without applying disruptive electrical contacts, allowing them to investigate both the resistance and quantum capacitance of graphene and other two-dimensional materials. Researchers from the Swiss Nanoscience Institute and the University of Basel’s Department of Physics reported their findings in the journal Physical Review Applied.
Graphene consists of a single layer of carbon atoms. It is transparent, harder than diamond and stronger than steel, yet flexible, and a significantly better...
The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.
The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
30.05.2017 | Life Sciences
30.05.2017 | Life Sciences
30.05.2017 | Physics and Astronomy